Fusion of TGF-beta 1 antigenic determinant and HBV core antigen as an anti-TGF-beta 1 vaccine.
- Author:
Yong-hong GUO
1
;
Jin-yan LUO
;
Zhi-ming HAO
;
Quan-ying WANG
;
Guang-xiao YANG
Author Information
- Publication Type:Journal Article
- MeSH: Epitopes; immunology; Genetic Vectors; Hepatitis B Core Antigens; biosynthesis; genetics; Humans; Liver Cirrhosis; prevention & control; Prokaryotic Cells; metabolism; Recombinant Fusion Proteins; biosynthesis; genetics; Transfection; Transforming Growth Factor beta; biosynthesis; genetics; Vaccines, Synthetic; biosynthesis; immunology
- From: Chinese Journal of Hepatology 2005;13(8):582-585
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVESTo examine the expression and purification of the TGFbeta1 vaccine from prokaryotic expression system and to determine the antigenicity of the fusion protein of recombinant vector pET28a/ HBcAg1-71-TGFbeta132-HBcAg89-144.
METHODSThe reconstructed vector pGEMEX-1/CTC was subcloned to pET28a and transformed into E. coli BL21 (DE3). The recombinant 6xHis- HBcAg1-71- TGFbeta132- HBcAg89-144 was to be expressed after induction by IPTG and purified with Ni-NTA-His affinity chromatography. The detection of the formation of core-like particles was done under an electron microscope and of their antigenity by using ELISA and Western blot.
RESULTSA 2.46 x 10(4) protein was obtained by optimizing the conditions for both expression and purification. The protein had the TGFbeta1 antigenicity but not a HBc antigenity and the formed core-like particles were bigger than natural core particles.
CONCLUSIONThe recombinant fusion protein in the prokaryotic expressed system can be used as an anti-TGFbeta1 vaccine to inhibit hepatic fibrosis.